Advertisement

Topics

Companies Related to "Daiichi Sankyo takes option diabetes stem cell start" [Most Relevant Company Matches] [Advanced Search Results] RSS

05:31 EDT 23rd March 2019 | BioPortfolio

Here are the most relevant search results for "Daiichi Sankyo takes option diabetes stem cell start" found in our extensive corporate database of over 50,000 company records.

Showing "Daiichi Sankyo takes option diabetes stem cell start" Companies 1–25 of 2,700+

Extremely Relevant

DAIICHI SANKYO EUROPE GmbH and SHARE

DAIICHI SANKYO is a global pharmaceutical company that focuses on researching and marketing innovative medications. The company was created in 2005 through the merger of two traditional Japanese enterprises, Daiichi and Sankyo. With net sales of more than 5.9 billion EUR in fiscal year 2008, DAIICHI SANKYO is one of the world's 20 leading pharmaceutical companies. The company's world headquart...


Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders a...

Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited, established in 2005 after the joint share transfer of two leading century-old Japanese pharmaceutical companies, is continuously generating innovative drugs that enrich the quality of life for patients around the world. The company uses its cumulative knowledge and expertise in the fields of cardiovascular disease, cancer, metabolic disorders, and infection as ...


ArQule, Inc. and Daiichi Sankyo Company, Limited

On December 19, 2008, ArQule and Daiichi Sankyo, Co., Ltd. signed a license, co-development and co-commercialization agreement to co-develop tivantinib in the U.S., Europe, South America and the rest of the world, excluding Japan, China (including Hong Kong), South Korea and Taiwan, where Kyowa Hakko Kirin Co., Ltd. has exclusive rights for development and...

National Stem Cell Holding, Inc.

National Stem Cell Holding, Inc. is a biotechnology company focused on the development and commercialization of cell therapeutics primarily for diabetes and cardiac disease, and cosmetics derived from stem cells. For more information, visit http://www.proteoderm.com, and http://www.proteonomix.com.

Daiichi Sankyo, Inc.

From the discovery of epinephrine to the development of the statin class of lipid-lowering agents, and the development of the first glitazone, which revolutionized long-term control of type 2 diabetes, the people of Daiichi Sankyo remain committed to a unique ideal – Adding to the Balance of Life.To physicians, this means objective data, the highest ethical standards, and a desire to deliver pra...

Daiichi-Sankyo

Entest BioMedical Inc.

Entest BioMedical Inc. (OTC Bulletin Board: ENTB) is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTC Bulletin Board: BMSN). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The C...

Opexa Therapeutics

Opexa Therapeutics is a commercialization driven biotechnology cellular therapy company that develops autologous personalized cell therapies for the treatment of various diseases. The Company is focused on its proprietary stem cell and T-cell technologies for the autologous use of peripheral blood derived adult stem cells in regenerative medicine as well as T cells for the treatment of autoimmune ...

Vitro Diagnostics

We develop stem cell technology for potential use in diabetes research and treatment. Our research has led to a patent-pending method for generation of adult stem cells from cells isolated from tissues. While embryonic stem cells are capable of differentiation into all of the various cells of the body, adult stem cells are more limited in differentiation capacity generally including the cell typ...

Relevant

Stem Cell Assurance, Inc.

Stem Cell Assurance, Inc. is the first company in the US to provide full-spectrum adult stem cell services to consumers through a national physician network. The company offers genetic profiling services and consultation, adult stem cell research, and stem cell collection, processing, and cryogenic storage, as well as cosmetic and other infusion therapies....

America Stem Cell, Inc.

America Stem Cell is a privately held biotechnology company based in San Antonio, TX, with offices in San Diego, CA, and is dedicated to the development and commercialization of stem cell enabling technologies/products to transform clinical outcomes for patients undergoing stem cell transplantation. The key stem cell enabling platform technologies/compound...

Vitro Diagnostics, Inc.

Vitro Diagnostics, Inc., dba Vitro Biopharma (OTCBB: VODG) (http://www.vitrobiopharma.com), owns U.S. patents for production of a fertility drug, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes. Vitro’s mission is “Harnessing the Power of Cells™” for the advancement of regenerative...

National Stem Cell Foundation

The National Stem Cell Foundation (NSCF) is a charitable 501(c)3 organization that funds adult stem cell and regenerative medicine research to accelerate treatment options, advocates for patients participating in clinical trials and supports STEM education to inspire the next generation of researchers and scientists nationwide. For more information, visit ...

Cellectis Group

Cellectis stem cells, is a business unit within the Cellectis group and is a global leader in stem cell technology. Cellectis stem cells, created in November 2011 from Cellartis AB and Ectycell SAS, possesses broad expertise in pluripotent stem cells, including iPS cell technology, genetic engineering and specialised cells. Cellectis stem cells is developi...

The New York Stem Cell Foundation

The New York Stem Cell Foundation (NYSCF) is an independent organization founded in 2005 to accelerate cures and better treatments for patients through stem cell research. NYSCF, a global community of over 140 leading stem cell researchers and neuroscientists, employs over 45 researchers at the NYSCF Research Institute, located in New York, and is an ackno...

International Society for Stem Cell Research

The International Society for Stem Cell Research is an independent, nonprofit membership organization established to promote and foster the exchange and dissemination of information and ideas relating to stem cells, to encourage the general field of research involving stem cells and to promote professional and public education in all areas of stem cell res...

Gamida Cell Ltd.

Gamida Cell is developing expanded stem cell therapies for the treatment of such illnesses as blood cancers, cardiac disease and diabetes. The Company is dedicated to making a significant difference in the clinical practice of modern medicine by first creating, then tapping the regeneration power of an ample body of therapeutic stem cells

Daiichi Sankyo Company, Limited, and Eli Lilly and Company

ReNeuron Group plc

ReNeuron Group plc is a leading player in the stem cell field, using human somatic stem cells to develop leading edge therapies for neurodegenerative and other diseases. We are also leveraging our stem cell technologies into non-therapeutic areas such as drug discovery - our ReNcell product.We have proprietary stem cell technologies which we believe confer significant advantages over competitor te...

Kadimastem

Kadimastem (www.kadimastem.com) is a biotechnology company focused on the industrial development and commercialization of human pluripotent stem cell-based products. At Kadimastem, the pluripotent stem cell technology is used to produce specialized human cells and tissues for two major types of medical applications: 1) Drug-screening platforms using human ...

Cell Therapy Foundation

The Cell Therapy Foundation is a not-for-profit organization committed to advancing the treatment of disease using adult stem cells. Emerging as a leader in raising funds for adult stem cell research, Cell Therapy Foundation strives to increase awareness about adult stem cells, to fund adult stem cell research addressing several specific diseases, and to accelerate the rate of research and clini...

Sankyo Co., Ltd.

Since Sankyo's founding, the Company has been continuously motivated by an unstinting drive to bring new pharmaceuticals to market. This introduction to Sankyo's progress to date will reveal the eagerness to confront new challenges that animates our operations, and the global stance to which this has led us.

Beike Biotechnology Company Limited

Beike Biotechnology (http://www.beikebiotech.com) is Asia's leading biotechnology company focusing on adult stem cell therapies. Beike's scientists have been focused on the development and commercialization of adult stem cell therapies since 1999. The company currently produces a full line of stem cell products from umbilical cord, cord blood, and bone marrow stem cells. Beike's stem cell ther...

Stem Cell Sciences plc

Stem Cell Sciences plc (AIM:STEM, ASX:STC), a company focused on the commercialisation of stem cells and stem cell technologies, is pleased to announce that two independent laboratories in the UK and USA have achieved germ-line transmission from embryonic stem (ES) cells in rats using technologies exclusively licensed to the company by Edinburgh University. This is believed to be the first tim...


More From BioPortfolio on "Daiichi Sankyo takes option diabetes stem cell start"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks